132 related articles for article (PubMed ID: 38232611)
1. Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
Benvenuti C; Laot L; Grinda T; Lambertini M; Pistilli B; Grynberg M
ESMO Open; 2024 Feb; 9(2):102228. PubMed ID: 38232611
[TBL] [Abstract][Full Text] [Related]
2. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.
Arecco L; Blondeaux E; Bruzzone M; Ceppi M; Latocca MM; Marrocco C; Boutros A; Spagnolo F; Razeti MG; Favero D; Spinaci S; Condorelli M; Massarotti C; Goldrat O; Del Mastro L; Demeestere I; Lambertini M
Hum Reprod; 2022 May; 37(5):954-968. PubMed ID: 35220429
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
4. Gonadotrophin stimulation and risk of relapse in breast cancer.
Fredriksson A; Rosenberg E; Einbeigi Z; Bergh C; Strandell A
Hum Reprod Open; 2021; 2021(1):hoaa061. PubMed ID: 33501382
[TBL] [Abstract][Full Text] [Related]
5. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM.
Sellami I; Mayeur A; Benoit A; Zeghari F; Peigné M; Roufael J; Grynberg M; Sonigo C
J Assist Reprod Genet; 2023 Mar; 40(3):473-480. PubMed ID: 36752941
[TBL] [Abstract][Full Text] [Related]
6. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
8. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
9. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
11. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
12. Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer.
Pereira N; Kligman I; Hunt R; Kopparam R; Wahmann B; Rosenwaks Z
Gynecol Endocrinol; 2019 Mar; 35(3):214-216. PubMed ID: 30403906
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.
Rothé F; Lambertini M; Goldrat O; Maetens M; Bareche Y; Blanc J; Rouas G; Larsimont D; Sotiriou C; Ignatiadis M; Demeestere I
Front Oncol; 2021; 11():686625. PubMed ID: 34414109
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Russo M; Liu K; Chan C
Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566
[TBL] [Abstract][Full Text] [Related]
15. A specific controlled ovarian stimulation (COS) protocol for fertility preservation in women with breast cancer undergoing neoadjuvant chemotherapy.
Cavagna F; Pontes A; Cavagna M; Dzik A; Donadio NF; Portela R; Nagai MT; Gebrim LH
Contemp Oncol (Pozn); 2017; 21(4):290-294. PubMed ID: 29416435
[TBL] [Abstract][Full Text] [Related]
16. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Gori S; Fabi A; Angiolini C; Turazza M; Salvini P; Ferretti G; Cretella E; Gianni L; Bighin C; Toss A; Zamagni C; Vici P; De Rossi C; Russo A; Bisagni G; Frassoldati A; Borgato L; Cariello A; Cappelletti C; Bordonaro R; Cinieri S; Modena A; Valerio M; Alvisi MF; De Simone I; Galli F; Rulli E; Santoni A; Nicolis F
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835546
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
19. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
Letourneau JM; Wald K; Sinha N; Juarez-Hernandez F; Harris E; Cedars MI; McCulloch CE; Dolezal M; Chien AJ; Rosen MP
Cancer; 2020 Feb; 126(3):487-495. PubMed ID: 31639215
[TBL] [Abstract][Full Text] [Related]
20. [Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study].
Xiu M; Lu Y; Wang X; Fan Y; Li Q; Li Q; Wang JY; Luo Y; Cai RG; Chen SS; Yuan P; Ma F; Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):709-716. PubMed ID: 37580278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
